Results 151 to 160 of about 6,270 (167)

Outcome and Safety of Different Cumulative Doses and Protocols of Intravenous Methylprednisolone in Moderate to Severe and Active Graves’ Ophthalmopathy

Ophthalmologica Indonesiana, 2019
Background: Graves’ ophthalmopathy (GO), also known as Graves’ orbitopathy or thyroid eye disease, has a potential sight-threatening complications. The activity and severity are important determinants in GO and are implications for treatment. Intravenous Glucocorticoid (GC) was associated with significantly greater efficacy and
Amelya Permata Sari, M Sidik, Syntia Nusanti   +2 more
openaire   +1 more source

Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives

Current Eye Research, 2020
Vimal K Maurya, Swatantra Kumar, Shailendra K Saxena   +2 more
exaly  

Association between Graves' ophthalmopathy and smoking

Lancet, The, 1990
A P Weetman
exaly  

Cytokines in the Evolution of Graves' Ophthalmopathy

Autoimmunity, 1997
Neena Natt, N Natt, Rebecca S Bahn
exaly  

MHC class II region, CTLA4 gene, and ophthalmopathy in patients with Graves' disease

Lancet, The, 2001
Amit Allahabadia, J M Heward, J A Franklyn   +2 more
exaly  

Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves’ ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study

Journal of Endocrinological Investigation, 2014
Claudio Marcocci, Luigi Bartalena, Fausto Bogazzi   +2 more
exaly  

Ophthalmopathy and hyperthyroidism

Acta Ophthalmologica, 1986
M SÖDerstrÖM
exaly  

Randomised double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy

Lancet, The, 1993
W M Wiersinga, L Koornneef, M F Prummel   +2 more
exaly  

Glycosaminoglycans in Thyroid-Associated Ophthalmopathy

Autoimmunity, 1992
C Stover
exaly  

Graves' Ophthalmopathy

New England Journal of Medicine, 2010
Rebecca S Bahn, Bahn Rebecca S
exaly